clinical pipeline
for diseases of the body, brain & eye

STOP COMPLEMENT-MEDIATED
DISEASES AT THE START

Annexon is pioneering a class of new complement medicines for patients with classical complement-mediated disorders of the body, brain and eye. We are conducting ongoing clinical trials in multiple serious autoimmune, neurodegenerative and ophthalmic diseases.

INNOVATIVE PORTFOLIO OF DRUG candidates advancing for diseases of high unmet need

Franchise
Candidate
Preclinical
Phase 1
Phase 2
Phase 2/3
Autoimmune
ANX005 (IV)
ANX005 (IV)
ANX005 (IV)
ANX009 (SC)
ANX1502 (oral)
Guillain-Barré Syndrome (GBS)
Warm Autoimmune Hemolytic Anemia (wAIHA)
Multifocal Motor Neuropathy (MMN)*
Lupus Nephritis (LN)*
Autoimmune
Neuro
degeneration
ANX005 (IV)
ANX005 (IV)
ANX105 (IV)
Huntington’s Disease (HD)
Amyotrophic Lateral Sclerosis (ALS)
Neuro
Ophthalmology
ANX007 (IVT)
Geographic Atrophy (GA)